Agilent Technologies, Inc. (0HAV.L)
USD 136.25
(-0.67%)
USD 136.25
(-0.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.83 Billion USD | -0.22% |
| 2022 | 6.84 Billion USD | 8.37% |
| 2021 | 6.31 Billion USD | 18.36% |
| 2020 | 5.33 Billion USD | 3.41% |
| 2019 | 5.16 Billion USD | 5.07% |
| 2018 | 4.91 Billion USD | 9.88% |
| 2017 | 4.47 Billion USD | 6.43% |
| 2016 | 4.2 Billion USD | 4.06% |
| 2015 | 4.03 Billion USD | -42.16% |
| 2014 | 6.98 Billion USD | 2.93% |
| 2013 | 6.78 Billion USD | -1.11% |
| 2012 | 6.85 Billion USD | 3.67% |
| 2011 | 6.61 Billion USD | 21.51% |
| 2010 | 5.44 Billion USD | 21.49% |
| 2009 | 4.48 Billion USD | -22.39% |
| 2008 | 5.77 Billion USD | 6.53% |
| 2007 | 5.42 Billion USD | 8.99% |
| 2006 | 4.97 Billion USD | -3.23% |
| 2005 | 5.13 Billion USD | -28.44% |
| 2004 | 7.18 Billion USD | 18.58% |
| 2003 | 6.05 Billion USD | 0.77% |
| 2002 | 6.01 Billion USD | -28.42% |
| 2001 | 8.39 Billion USD | -22.06% |
| 2000 | 10.77 Billion USD | 29.31% |
| 1999 | 8.33 Billion USD | 4.77% |
| 1998 | 7.95 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.57 Billion USD | -5.13% |
| 2024 Q3 | 1.57 Billion USD | 0.32% |
| 2024 Q1 | 1.65 Billion USD | -1.78% |
| 2023 FY | 6.83 Billion USD | -0.22% |
| 2023 Q3 | 1.67 Billion USD | -2.62% |
| 2023 Q1 | 1.75 Billion USD | -5.03% |
| 2023 Q2 | 1.71 Billion USD | -2.22% |
| 2023 Q4 | 1.68 Billion USD | 0.96% |
| 2022 Q1 | 1.67 Billion USD | 0.84% |
| 2022 Q3 | 1.71 Billion USD | 6.91% |
| 2022 FY | 6.84 Billion USD | 8.37% |
| 2022 Q4 | 1.84 Billion USD | 7.63% |
| 2022 Q2 | 1.6 Billion USD | -4.0% |
| 2021 Q4 | 1.66 Billion USD | 4.67% |
| 2021 Q1 | 1.54 Billion USD | 4.38% |
| 2021 Q2 | 1.52 Billion USD | -1.49% |
| 2021 Q3 | 1.58 Billion USD | 4.0% |
| 2021 FY | 6.31 Billion USD | 18.36% |
| 2020 Q2 | 1.23 Billion USD | -8.77% |
| 2020 Q4 | 1.48 Billion USD | 17.61% |
| 2020 FY | 5.33 Billion USD | 3.41% |
| 2020 Q3 | 1.26 Billion USD | 1.86% |
| 2020 Q1 | 1.35 Billion USD | -0.73% |
| 2019 FY | 5.16 Billion USD | 5.07% |
| 2019 Q4 | 1.36 Billion USD | 7.3% |
| 2019 Q3 | 1.27 Billion USD | 2.91% |
| 2019 Q2 | 1.23 Billion USD | -3.58% |
| 2019 Q1 | 1.28 Billion USD | -0.77% |
| 2018 Q4 | 1.29 Billion USD | 7.56% |
| 2018 Q1 | 1.21 Billion USD | 1.85% |
| 2018 Q3 | 1.2 Billion USD | -0.25% |
| 2018 Q2 | 1.2 Billion USD | -0.41% |
| 2018 FY | 4.91 Billion USD | 9.88% |
| 2017 Q1 | 1.06 Billion USD | -3.96% |
| 2017 Q4 | 1.18 Billion USD | 6.73% |
| 2017 Q3 | 1.11 Billion USD | 1.09% |
| 2017 FY | 4.47 Billion USD | 6.43% |
| 2017 Q2 | 1.1 Billion USD | 3.28% |
| 2016 FY | 4.2 Billion USD | 4.06% |
| 2016 Q4 | 1.11 Billion USD | 6.42% |
| 2016 Q2 | 1.01 Billion USD | -0.88% |
| 2016 Q1 | 1.02 Billion USD | -0.68% |
| 2016 Q3 | 1.04 Billion USD | 2.45% |
| 2015 Q4 | 1.03 Billion USD | 2.07% |
| 2015 Q2 | 963 Million USD | -6.14% |
| 2015 Q1 | 1.02 Billion USD | -43.16% |
| 2015 FY | 4.03 Billion USD | -42.16% |
| 2015 Q3 | 1.01 Billion USD | 5.3% |
| 2014 FY | 6.98 Billion USD | 2.93% |
| 2014 Q3 | 1.76 Billion USD | 2.02% |
| 2014 Q4 | 1.8 Billion USD | 2.21% |
| 2014 Q1 | 1.67 Billion USD | -2.27% |
| 2014 Q2 | 1.73 Billion USD | 3.1% |
| 2013 FY | 6.78 Billion USD | -1.11% |
| 2013 Q2 | 1.73 Billion USD | 3.1% |
| 2013 Q3 | 1.65 Billion USD | -4.62% |
| 2013 Q4 | 1.71 Billion USD | 4.0% |
| 2013 Q1 | 1.68 Billion USD | -4.92% |
| 2012 FY | 6.85 Billion USD | 3.67% |
| 2012 Q4 | 1.76 Billion USD | 2.55% |
| 2012 Q3 | 1.72 Billion USD | -0.58% |
| 2012 Q2 | 1.73 Billion USD | 5.99% |
| 2012 Q1 | 1.63 Billion USD | -5.38% |
| 2011 FY | 6.61 Billion USD | 21.51% |
| 2011 Q3 | 1.69 Billion USD | 0.83% |
| 2011 Q1 | 1.51 Billion USD | -3.62% |
| 2011 Q2 | 1.67 Billion USD | 10.4% |
| 2011 Q4 | 1.72 Billion USD | 2.19% |
| 2010 Q4 | 1.57 Billion USD | 13.87% |
| 2010 Q3 | 1.38 Billion USD | 8.89% |
| 2010 Q2 | 1.27 Billion USD | 4.78% |
| 2010 FY | 5.44 Billion USD | 21.49% |
| 2010 Q1 | 1.21 Billion USD | 3.94% |
| 2009 Q4 | 1.16 Billion USD | 10.41% |
| 2009 FY | 4.48 Billion USD | -22.39% |
| 2009 Q1 | 1.16 Billion USD | -21.27% |
| 2009 Q2 | 1.09 Billion USD | -6.43% |
| 2009 Q3 | 1.05 Billion USD | -3.12% |
| 2008 FY | 5.77 Billion USD | 6.53% |
| 2008 Q1 | 1.39 Billion USD | -3.67% |
| 2008 Q3 | 1.44 Billion USD | -0.82% |
| 2008 Q2 | 1.45 Billion USD | 4.52% |
| 2008 Q4 | 1.48 Billion USD | 2.56% |
| 2007 Q2 | 1.32 Billion USD | 3.13% |
| 2007 Q4 | 1.44 Billion USD | 5.24% |
| 2007 Q3 | 1.37 Billion USD | 4.09% |
| 2007 Q1 | 1.28 Billion USD | 69.99% |
| 2007 FY | 5.42 Billion USD | 8.99% |
| 2006 Q2 | 1.43 Billion USD | 7.11% |
| 2006 Q3 | 1.45 Billion USD | 1.54% |
| 2006 Q4 | 753 Million USD | -48.18% |
| 2006 FY | 4.97 Billion USD | -3.23% |
| 2006 Q1 | 1.33 Billion USD | 1172.38% |
| 2005 Q3 | 1.68 Billion USD | 0.0% |
| 2005 Q4 | 105 Million USD | -93.78% |
| 2005 FY | 5.13 Billion USD | -28.44% |
| 2005 Q1 | 1.65 Billion USD | -9.0% |
| 2005 Q2 | 1.68 Billion USD | 1.81% |
| 2004 Q4 | 1.82 Billion USD | -3.34% |
| 2004 Q3 | 1.88 Billion USD | 2.95% |
| 2004 Q1 | 1.64 Billion USD | -1.91% |
| 2004 FY | 7.18 Billion USD | 18.58% |
| 2004 Q2 | 1.83 Billion USD | 11.44% |
| 2003 Q1 | 1.41 Billion USD | -18.66% |
| 2003 FY | 6.05 Billion USD | 0.77% |
| 2003 Q4 | 1.67 Billion USD | 11.52% |
| 2003 Q3 | 1.5 Billion USD | 2.39% |
| 2003 Q2 | 1.46 Billion USD | 3.9% |
| 2002 FY | 6.01 Billion USD | -28.42% |
| 2002 Q4 | 1.73 Billion USD | 24.8% |
| 2002 Q3 | 1.39 Billion USD | -4.53% |
| 2002 Q2 | 1.45 Billion USD | 2.17% |
| 2002 Q1 | 1.42 Billion USD | -14.1% |
| 2001 Q1 | 2.84 Billion USD | -15.75% |
| 2001 Q4 | 1.66 Billion USD | -8.08% |
| 2001 Q3 | 1.8 Billion USD | -24.18% |
| 2001 Q2 | 2.38 Billion USD | -16.16% |
| 2001 FY | 8.39 Billion USD | -22.06% |
| 2000 Q3 | 2.67 Billion USD | 7.44% |
| 2000 Q1 | 2.24 Billion USD | -8.25% |
| 2000 FY | 10.77 Billion USD | 29.31% |
| 2000 Q2 | 2.48 Billion USD | 10.64% |
| 2000 Q4 | 3.37 Billion USD | 26.29% |
| 1999 Q4 | 2.44 Billion USD | 17.3% |
| 1999 Q3 | 2.08 Billion USD | 3.83% |
| 1999 FY | 8.33 Billion USD | 4.77% |
| 1999 Q2 | 2.01 Billion USD | 12.54% |
| 1999 Q1 | 1.78 Billion USD | 0.0% |
| 1998 FY | 7.95 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -8646.464% |
| Dynavax Technologies Corporation | 232.28 Million USD | -2841.658% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -1024.735% |
| Perrigo Company plc | 4.65 Billion USD | -46.769% |
| Illumina, Inc. | 4.5 Billion USD | -51.71% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 84.056% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -574584.609% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 95.372% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 54.398% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -5278.452% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 47.908% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | -131.124% |
| Biogen Inc. | 9.83 Billion USD | 30.528% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -3777.275% |
| Evolus, Inc. | 202.08 Million USD | -3281.25% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -32487.753% |
| bluebird bio, Inc. | 29.49 Million USD | -23065.068% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -5773.605% |
| FibroGen, Inc. | 147.75 Million USD | -4524.641% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 102836.431% |
| Geron Corporation | 237 Thousand USD | -2883022.363% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -273.737% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -1611.005% |
| Myriad Genetics, Inc. | 678.4 Million USD | -907.223% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -18736.664% |
| Zoetis Inc. | 8.54 Billion USD | 20.026% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -195128.571% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -80.371% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -182.446% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 30.764% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -767.521% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -79603.721% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -7481.944% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -2425.129% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -21766.3% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -449.57% |
| OPKO Health, Inc. | 863.49 Million USD | -691.319% |
| Exelixis, Inc. | 1.83 Billion USD | -273.346% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -262.09% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -1316.533% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -43029.458% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -2639.995% |
| Insmed Incorporated | 305.2 Million USD | -2138.801% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -723.995% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -25374.406% |
| TG Therapeutics, Inc. | 233.66 Million USD | -2824.309% |
| Incyte Corporation | 3.69 Billion USD | -84.893% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -551.196% |